Intrinsic value of Medifast - MED

Previous Close

$62.64

  Intrinsic Value

$37.80

stock screener

  Rating & Target

sell

-40%

Previous close

$62.64

 
Intrinsic value

$37.80

 
Up/down potential

-40%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MED stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.73
  7.00
  6.80
  6.62
  6.46
  6.31
  6.18
  6.06
  5.96
  5.86
  5.77
  5.70
  5.63
  5.56
  5.51
  5.46
  5.41
  5.37
  5.33
  5.30
  5.27
  5.24
  5.22
  5.20
  5.18
  5.16
  5.14
  5.13
  5.12
  5.10
  5.09
Revenue, $m
  275
  294
  314
  335
  357
  379
  403
  427
  453
  479
  507
  536
  566
  597
  630
  664
  700
  738
  777
  819
  862
  907
  954
  1,004
  1,056
  1,110
  1,167
  1,227
  1,290
  1,356
  1,425
Variable operating expenses, $m
 
  263
  281
  300
  319
  339
  360
  382
  405
  429
  453
  479
  506
  534
  564
  595
  627
  661
  696
  733
  771
  812
  854
  898
  945
  994
  1,045
  1,098
  1,155
  1,214
  1,275
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  248
  263
  281
  300
  319
  339
  360
  382
  405
  429
  453
  479
  506
  534
  564
  595
  627
  661
  696
  733
  771
  812
  854
  898
  945
  994
  1,045
  1,098
  1,155
  1,214
  1,275
Operating income, $m
  27
  31
  33
  35
  37
  40
  42
  45
  48
  50
  53
  56
  59
  63
  66
  70
  74
  77
  82
  86
  90
  95
  100
  105
  111
  117
  123
  129
  135
  142
  150
EBITDA, $m
  32
  36
  39
  41
  44
  47
  49
  52
  56
  59
  62
  66
  69
  73
  77
  82
  86
  91
  95
  101
  106
  111
  117
  123
  130
  136
  143
  151
  158
  167
  175
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
Earnings before tax, $m
  27
  31
  33
  35
  37
  40
  42
  44
  47
  50
  53
  55
  59
  62
  65
  69
  72
  76
  80
  84
  89
  93
  98
  103
  109
  114
  120
  126
  132
  139
  146
Tax expense, $m
  9
  8
  9
  9
  10
  11
  11
  12
  13
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  27
  28
  29
  31
  32
  34
  36
  38
  39
Net income, $m
  18
  23
  24
  26
  27
  29
  31
  32
  34
  36
  38
  41
  43
  45
  48
  50
  53
  56
  59
  62
  65
  68
  72
  75
  79
  83
  88
  92
  97
  102
  107

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  77
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  121
  47
  50
  54
  57
  61
  64
  68
  72
  77
  81
  86
  91
  96
  101
  106
  112
  118
  124
  131
  138
  145
  153
  161
  169
  178
  187
  196
  206
  217
  228
Adjusted assets (=assets-cash), $m
  44
  47
  50
  54
  57
  61
  64
  68
  72
  77
  81
  86
  91
  96
  101
  106
  112
  118
  124
  131
  138
  145
  153
  161
  169
  178
  187
  196
  206
  217
  228
Revenue / Adjusted assets
  6.250
  6.255
  6.280
  6.204
  6.263
  6.213
  6.297
  6.279
  6.292
  6.221
  6.259
  6.233
  6.220
  6.219
  6.238
  6.264
  6.250
  6.254
  6.266
  6.252
  6.246
  6.255
  6.235
  6.236
  6.249
  6.236
  6.241
  6.260
  6.262
  6.249
  6.250
Average production assets, $m
  25
  26
  28
  30
  32
  34
  36
  38
  40
  43
  45
  48
  50
  53
  56
  59
  62
  66
  69
  73
  77
  81
  85
  89
  94
  99
  104
  109
  115
  121
  127
Working capital, $m
  77
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total debt, $m
  0
  2
  4
  5
  7
  9
  12
  14
  16
  19
  21
  24
  26
  29
  32
  35
  39
  42
  46
  49
  53
  57
  62
  66
  71
  76
  81
  87
  92
  98
  105
Total liabilities, $m
  25
  27
  29
  30
  32
  34
  37
  39
  41
  44
  46
  49
  51
  54
  57
  60
  64
  67
  71
  74
  78
  82
  87
  91
  96
  101
  106
  112
  117
  123
  130
Total equity, $m
  96
  20
  22
  23
  25
  26
  28
  30
  31
  33
  35
  37
  39
  41
  44
  46
  48
  51
  54
  57
  60
  63
  66
  69
  73
  77
  81
  85
  89
  94
  98
Total liabilities and equity, $m
  121
  47
  51
  53
  57
  60
  65
  69
  72
  77
  81
  86
  90
  95
  101
  106
  112
  118
  125
  131
  138
  145
  153
  160
  169
  178
  187
  197
  206
  217
  228
Debt-to-equity ratio
  0.000
  0.090
  0.160
  0.240
  0.300
  0.360
  0.420
  0.470
  0.520
  0.560
  0.600
  0.640
  0.680
  0.710
  0.740
  0.770
  0.800
  0.820
  0.850
  0.870
  0.900
  0.920
  0.940
  0.950
  0.970
  0.990
  1.000
  1.020
  1.030
  1.050
  1.060
Adjusted equity ratio
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  18
  23
  24
  26
  27
  29
  31
  32
  34
  36
  38
  41
  43
  45
  48
  50
  53
  56
  59
  62
  65
  68
  72
  75
  79
  83
  88
  92
  97
  102
  107
Depreciation, amort., depletion, $m
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
Funds from operations, $m
  21
  28
  30
  32
  34
  36
  38
  40
  42
  45
  47
  50
  53
  56
  59
  62
  65
  69
  72
  76
  80
  84
  89
  93
  98
  103
  108
  114
  120
  126
  132
Change in working capital, $m
  -4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from operations, $m
  25
  28
  30
  32
  34
  36
  38
  40
  42
  45
  47
  50
  53
  56
  59
  62
  65
  69
  72
  76
  80
  84
  89
  93
  98
  103
  108
  114
  120
  126
  132
Maintenance CAPEX, $m
  0
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -14
  -15
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
New CAPEX, $m
  -3
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
Cash from investing activities, $m
  -2
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -12
  -13
  -13
  -14
  -14
  -15
  -15
  -17
  -18
  -19
  -19
  -20
  -21
  -23
  -24
  -25
  -26
  -28
  -29
  -30
Free cash flow, $m
  23
  21
  23
  24
  26
  27
  29
  31
  33
  34
  36
  38
  41
  43
  45
  48
  50
  53
  56
  59
  62
  65
  68
  72
  76
  79
  83
  88
  92
  97
  102
Issuance/(repayment) of debt, $m
  0
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
Issuance/(repurchase) of shares, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
Total cash flow (excl. dividends), $m
  22
  23
  24
  26
  28
  29
  31
  33
  35
  37
  39
  41
  43
  46
  48
  51
  53
  56
  59
  62
  66
  69
  73
  76
  80
  84
  89
  93
  98
  103
  108
Retained Cash Flow (-), $m
  -7
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
Prev. year cash balance distribution, $m
 
  77
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  99
  23
  25
  26
  28
  29
  31
  33
  35
  37
  39
  41
  44
  46
  48
  51
  54
  57
  60
  63
  66
  69
  73
  77
  81
  85
  89
  94
  98
  103
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  95
  21
  21
  22
  22
  21
  21
  21
  20
  19
  19
  18
  17
  15
  14
  13
  12
  10
  9
  8
  7
  6
  5
  4
  3
  2
  2
  1
  1
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Medifast, Inc. is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins. The Company provides weight loss, weight management and healthy living products and programs through multiple channels of distribution, which include Take Shape For Life; its direct to consumer business unit through its Website and in-house call centers; Franchise Medifast Weight Control Centers, and a national network of physicians. The Company offers a range of weight loss, weight management and healthy products under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home and Essential 1 brands. The Company also offers a sports nutrition pilot product line, Dual Fuel.

FINANCIAL RATIOS  of  Medifast (MED)

Valuation Ratios
P/E Ratio 41.3
Price to Sales 2.7
Price to Book 7.7
Price to Tangible Book
Price to Cash Flow 29.7
Price to Free Cash Flow 33.8
Growth Rates
Sales Growth Rate 0.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate -22.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 15.2%
Ret/ On Assets - 3 Yr. Avg. 14.3%
Return On Total Capital 19.5%
Ret/ On T. Cap. - 3 Yr. Avg. 19.2%
Return On Equity 19.5%
Return On Equity - 3 Yr. Avg. 19.2%
Asset Turnover 2.3
Profitability Ratios
Gross Margin 74.9%
Gross Margin - 3 Yr. Avg. 74%
EBITDA Margin 11.6%
EBITDA Margin - 3 Yr. Avg. 13.1%
Operating Margin 9.8%
Oper. Margin - 3 Yr. Avg. 10.3%
Pre-Tax Margin 9.8%
Pre-Tax Margin - 3 Yr. Avg. 10.7%
Net Profit Margin 6.5%
Net Profit Margin - 3 Yr. Avg. 6.1%
Effective Tax Rate 33.3%
Eff/ Tax Rate - 3 Yr. Avg. 33.7%
Payout Ratio 66.7%

MED stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MED stock intrinsic value calculation we used $275 million for the last fiscal year's total revenue generated by Medifast. The default revenue input number comes from 2016 income statement of Medifast. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MED stock valuation model: a) initial revenue growth rate of 7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MED is calculated based on our internal credit rating of Medifast, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Medifast.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MED stock the variable cost ratio is equal to 89.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MED stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Medifast.

Corporate tax rate of 27% is the nominal tax rate for Medifast. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MED stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MED are equal to 8.9%.

Life of production assets of 4.9 years is the average useful life of capital assets used in Medifast operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MED is equal to 0%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $96 million for Medifast - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 11.93 million for Medifast is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Medifast at the current share price and the inputted number of shares is $0.7 billion.

RELATED COMPANIES Price Int.Val. Rating
NTRI Nutrisystem 58.95 132.79  str.buy
CAG Conagra Brands 33.91 13.60  str.sell

COMPANY NEWS

▶ ETFs with exposure to Medifast, Inc. : October 9, 2017   [Oct-09-17 11:46AM  Capital Cube]
▶ ETFs with exposure to Medifast, Inc. : September 19, 2017   [Sep-19-17 05:58PM  Capital Cube]
▶ Medifast confirms headquarters move to Harbor East   [09:35AM  American City Business Journals]
▶ Medifast, Inc. Announces Quarterly Dividend   [Sep-07-17 04:30PM  PR Newswire]
▶ Stock Indexes Retreat Fast; Medifast Thrusts Higher   [Aug-17-17 12:22PM  Investor's Business Daily]
▶ Medifast posts 2Q profit   [Aug-08-17 10:36PM  Associated Press]
▶ Take Shape For Life® Rebrands to OPTAVIA   [Jul-24-17 08:30AM  PR Newswire]
▶ ETFs with exposure to Medifast, Inc. : July 6, 2017   [Jul-06-17 01:59PM  Capital Cube]
▶ Medifast, Inc. Announces Quarterly Dividend   [Jun-07-17 04:05PM  PR Newswire]
▶ 5 Must See Earnings Charts   [May-23-17 05:55PM  Zacks]
▶ Medifast posts 1Q profit   [May-04-17 06:14PM  Associated Press]
▶ Medifast, Inc. Value Analysis (NYSE:MED) : April 19, 2017   [Apr-19-17 03:09PM  Capital Cube]
▶ Medifast CEO receives nearly $3 million in 2016   [Apr-10-17 12:25PM  American City Business Journals]
▶ Top Ranked Income Stocks to Buy for April 5th   [Apr-05-17 09:06AM  Zacks]
▶ Medifast posts 4Q profit   [06:28PM  Associated Press]
▶ Medifast, Inc. Announces Quarterly Dividend   [Mar-07-17 04:05PM  PR Newswire]
▶ Medifast Inc (MED): Are Hedge Funds Right About This Stock?   [Dec-06-16 11:30AM  at Insider Monkey]
▶ 5 Medical Tech Stocks You Should Be Investing In   [Dec-01-16 11:47AM  at Insider Monkey]
▶ Medifast's MacDonald out as CEO   [Oct-03-16 05:56PM  at bizjournals.com]
▶ Medifast, Inc. Announces Quarterly Dividend   [Sep-08-16 05:00PM  PR Newswire]
▶ Medifast profit drops 45 percent in 2Q   [06:55PM  at bizjournals.com]
Financial statements of MED
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.